Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

Nature

Volumn 402, Issue 6759, 1999, Pages 304-309

  Kung, Young Yun ^a   Felge, Ulrich ^b   Sarosi, Ildiko ^b   Bolon, Brad ^b   Taturi, Anna ^a   Morony, Sean ^b   Capparelli, Casey ^b   Li, Ji ^b   Elliott, Robin ^b   McCabe, Susan ^b   Wong, Thomas ^c   Campagnuolo, Gluseppe ^b   Moran, Erika ^d   Bogoch, Earl R ^d   Van, Gwyneth ^b   Nguyen, Linh T ^e   Ohashi, Pamela S ^e   Lacey, David L ^b   Fish, Eleanor ^c   Boyle, William J ^b   Penninger, Josef M ^a,e   more..

^a AMGEN INSTITUTE   (Canada)

^b AMGEN INC   (United States)

^c Dept Med Genet Microbiol ^*  (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; TUMOR NECROSIS FACTOR;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DESTRUCTION; BONE REMODELING; CARTILAGE DEGENERATION; CONTROLLED STUDY; JOINT DESTRUCTION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; BONE RESORPTION; CARRIER PROTEINS; CARTILAGE; CELLS, CULTURED; COCULTURE TECHNIQUES; GLYCOPROTEINS; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OSTEOPROTEGERIN; RANK LIGAND; RATS; RATS, INBRED LEW; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES;

EID: 0033581952     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/46303     Document Type: Article

References (24)

1. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
2. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
3. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 397, 315-323 (1999).
4. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell fucntion. Nature 390, 175-179 (1997).
5. Wong, B. r. et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor, J. Exp. Med. 186, 2075-2080 (1997).
6. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999).
7. Wong, B. R. et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194 (1997).
8. Felix, R., Hofstetter, W. & Cecchini, M. G. Recent developments in the understanding of the pathophysiology of osteopetrosis, Eur. J. Endocrinol. 134, 143-156 (1996).
9. Roodman, G. D. Advances in bone biology: the osteoclast. Endocr. Rev. 17, 308-332 (1996).
10. Roodman, G. D. Paget's disease and osteoclast biology. Bone 19, 209-212 (1996).
11. Coleman, R. E., Smith, P. & Rubens, R. D. Clinical course and prognostic factors following bone recurrence from breast cancer. Br. J. Cancer 77, 336-340 (199B).
12. Stellon, A. J., Davies, A., Compston, J. & Williams, R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 89, 1078-1083 (1985).
13. Oliveri, M. B., Mautalen, C. A., Rodriguez Fuchs, C. A. & Romanelli, M. C. Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp. Med. J. 39, 45-48 (1991).
14. Piepkorn, B. et al. Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 29, 584-591 (1997).
15. Feldmann, M., Brennan, F. M. & Maini, R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440 (1996).
16. Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345-1352 (1999).
17. Josien, R., Wong, B. R., Li, H. L., Steinman, R. M. & Choi, Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162, 2562-2568 (1999).
18. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995).
19. Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869-877 (1992).
20. Bendele, A. et al. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum. 42, 498-506 (1999).
21. Panayi, G. S., Lanchbury, J. S. & Kingsley, G. H. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 35, 729-735 (1992).
22. Muller-Ladner, U., Gay, R. E. & Gay, S. Molecular biology of cartilage and bone destruction. Curr. Opin. Rheumatol. 10, 212-219 (1998).
23. Conway, J. G. et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J. Exp. Med. 182, 449-457 (1995).
24. Faust, J. et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J. Cell. Biochem. 72, 67-80 (1999).